Scientific paper - Original scientific paper
Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma
Oncology Letters, 22 (2021), 6; 822. https://doi.org/10.3892/ol.2021.13083

Sremac, Maja; Paić, Frane; Ravić, Katja; Šerman, Ljiljana; Pavičić Dujmović, Aja; Brčić, Iva; Krznarić, Željko; Martić, Tamara

Cite this document

Sremac, M., Paić, F., Ravić, K., Šerman, Lj., Pavičić Dujmović, A., Brčić, I. ... Martić, T. (2021). Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology Letters, 22. (6). doi: 10.3892/ol.2021.13083

Sremac, Maja, et al. "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma." Oncology Letters, vol. 22, no. 6, 2021. https://doi.org/10.3892/ol.2021.13083

Sremac, Maja, Frane Paić, Katja Ravić, Ljiljana Šerman, Aja Pavičić Dujmović, Iva Brčić, Željko Krznarić and Tamara Martić. "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma." Oncology Letters 22, no. 6 (2021). https://doi.org/10.3892/ol.2021.13083

Sremac, M., et al. (2021) 'Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma', Oncology Letters, 22(6). doi: 10.3892/ol.2021.13083

Sremac M, Paić F, Ravić K, Šerman Lj, Pavičić Dujmović A, Brčić I, and sur.. Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma. Oncology Letters [Internet]. 2021 October 08 [cited 2024 November 26];22(6). doi: 10.3892/ol.2021.13083

M. Sremac, et al., "Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma", Oncology Letters, vol. 22, no. 6, October 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:791452. [Accessed: 26 November 2024]